CTOs on the Move

Biolife Plasma Services

www.hugheskc.com

 
Biolife Plasma Services is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.hugheskc.com
  • 6106 NW Tiffany Springs Pkwy
    Kansas City, MO USA 64154
  • Phone: 816.795.7002

Executives

Name Title Contact Details

Similar Companies

XtalPi

XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform.

Cognition Therapeutics

Cognition Therapeutics Inc. is a drug discovery and development company located in Pittsburgh, Pennsylvania. Founded in 2007, the company uses proprietary biology and chemistry platforms to discover novel drug targets and disease modifying therapies for disorders of the central nervous system.

Aktis Oncology

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.

PSI CRO AG

PSI is a leading full-service global Contract Research Organization whose key strength is predictable patient enrollment across multiple therapeutic areas. PSI is known in the industry as a CRO focused on ‘on-time project delivery. This is achieved through investing substantial effort and MD resources into performing quality feasibility assessments that provide an accurate predictor of study timelines. PSIs global reach allows us to run clinical trials across multiple continents, in 50+ countries around the world. PSIs reputation is that of a no-nonsense​ CRO focused on timely patient enrollment and project delivery. An exceptionally high repeat and referral business rates alongside low staff turnover are indicative of our commitment to be the best CRO in the world as measured by our clients and our employees. http://www.psi-cro.com

Fusion Pharmaceuticals

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion`s lead program, FPI-1434, is currently in a Phase 1 clinical trial. Fusion is headquartered in Hamilton, ON, with offices in Boston, MA.